Pharmaceutical company Eli Lilly announced the first patient enrolled for the 3rd phase of the study on the possibility of treatment with COVID-19 drug Baryticinib. The study will show the potential of an already existing drug used to treat rheumatoid arthritis, which can combine antiviral activity. It is planned to involve 400 patients, the results are expected in the next few months.